Dopamine Agonists in the Treatment of Restless Legs Syndrome: Too Much of a Good Thing?

키워드

참고문헌 (31)

1. Trenkwalder C, "Comorbidities, treatment, and pathophysiology in restless legs syndrome", Lancet Neurol, 17, pp.994~1005 (2018)[DOI]
2. Tison F, "Epidemiology of restless legs syndrome in French adults. A nationwide survey: the INSTANT study", Neurology, 65, pp.239~246 (2005)[DOI]
3. Leclair-Visonneau L, "French consensus : how to diagnose restless legs syndrome", Rev Neurol(Paris), 174, pp.508~514 (2018)[DOI]
4. Walters AS, "Toward a better definition of the restless legs syndrome", Mov Disord, 10, pp.634~642 (1995)[DOI]
5. Allen RP, "Restless legs syndrome : diagnostic criteria, special considerations, and epidemiology : a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health", Sleep Med, 4, pp.101~119 (2003)[DOI]
6. Allen RP, "Restless legs syndrome", Willis-Ekbom disease diagnostic criteria : updated International Restless Legs Syndrome Study Group(IRLSSG)consensus criteria--history, rationale, description, and significance, 2014, pp.15, 860~873
7. Schormair B, "Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry : a meta-analysis", Lancet Neurol, 16, pp.898~907 (2017)[DOI]
8. Trenkwalder C, "Restless legs syndrome associated with major diseases : a systematic review and new concept", Neurology, 86, pp.1336~1343 (2016)[DOI]
9. Didato G, "Restless legs syndrome across the lifespan : symptoms, pathophysiology, management and daily life impact of the different patterns of disease presentation", Int J Environ Res Public Health, 17, pp.3658~ (2020)[DOI]
10. Manconi M, "Restless legs syndrome", Nat Rev Dis Primers, 7, pp.80~ (2021)[DOI]
11. Stiasny K, "Restless legs syndrome and its treatment by dopamine agonists", Parkinsonism Relat Disord, 7, pp.21~25 (2000)[DOI]
12. Gossard TR, "Restless legs syndrome : contemporary diagnosis and treatment", Neurotherapeutics, 18, pp.140~155 (2021)[DOI]
13. Garcia-Borreguero D, "Restless legs syndrome(Willis-Ekbom disease) : an urgent need for better treatments", Sleep Med, 30, pp.266~267 (2017)[DOI]
14. Cornelius JR, "Impulse control disorders with the use of dopaminergic agents in restless legs syndrome : a case-control study", Sleep, 33, pp.81~87 (2010)[DOI]
15. Mitterling T, "Natural course of restless legs syndrome", Willis-Ekbom disease : long-term observation of a large clinical cohort, 2015, pp.16, 1252~1258
16. Baig F, "Impulse control disorders in Parkinson disease and RBD : a longitudinal study of severity", Neurology, 93, pp.e675~e687 (2019)[DOI]
17. Earley CJ, "Altered brain iron homeostasis and dopaminergic function in restless legs syndrome(Willis-Ekbom disease)", Sleep Med, 15, pp.1288~1301 (2014)[DOI]
18. Dziedzicka-Wasylewska M, "Brain dopamine receptors--research perspectives and potential sites of regulation", Pol J Pharmacol, 56, pp.659~671 (2004)
19. Garcia-Borreguero D, "New concepts in the management of restless legs syndrome", BMJ, 356, pp.j104~ (2017)[DOI]
20. Ferré S, "New insights into the neurobiology of restless legs syndrome", Neuroscientist, 25, pp.113~125 (2019)[DOI]
21. Lv Q, "Pharmacologic treatment of restless legs syndrome", Curr Neuropharmacol, 19, pp.372~382 (2021)[DOI]
22. Limousin N, "French consensus : treatment of newly diagnosed restless legs syndrome", Rev Neurol(Paris), 174, pp.515~521 (2018)[DOI]
23. Winkelman JW, "Practice guideline summary : treatment of restless legs syndrome in adults : report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology", Neurology, 87, pp.2585~2593 (2016)[DOI]
24. Winkelman JW, "Long-term safety, dose stability, and efficacy of opioids for patients with restless legs syndrome in the national RLS Opioid Registry", Neurology, 100, pp.e1520~e1528 (2023)[DOI]
25. Walters AS, "Validation of the international restless legs syndrome study group rating scale for restless legs syndrome", Sleep Med, 4, pp.121~132 (2003)[DOI]
26. Garcia-Borreguero D, "Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel", Sleep Med, 34, pp.105~108 (2017)[DOI]
27. Garcia-Borreguero D, "Treatment of restless legs syndrome", Willis-Ekbom disease with the non-selective ENT1, Sleep Med, pp.2018, 45[DOI]
28. Yadav SK, "A mechanistic review on medicinal mushrooms-derived bioactive compounds : potential mycotherapy candidates for alleviating neurological disorders", Planta Med, 86, pp.1161~1175 (2020)[DOI]
29. Zhang R, "Ganoderma lucidum protects dopaminergic neuron degeneration through inhibition of microglial activation", Evid Based Complement Alternat Med, 2011, pp.156810~ (2011)[DOI]
30. Ahmad R, "Ganoderma lucidum(Reishi)an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties", Phytother Res, 35, pp.6030~6062 (2021)[DOI]
31. Bugnicourt JM, "Medicinal mushroom, Ganoderma lucidum, improves painful symptoms in patients with restless legs syndrome", J Clin Stud Med Case Rep, 10, pp.179~ (2023)[DOI]

관련 논문AI추천